ClinicalTrials.gg
CompletedNCT00734071Updated Dec 18, 2013Results posted

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

A Phase 3 interventional study of Vortioxetine and Placebo in Generalized Anxiety Disorder, sponsored by Takeda. Completed at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
52nd of 234
304 · median 90
Started
2008
with 19 others
Phase 3
45 of 265
6 open now
Registered
66th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 52nd largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2008, is one of 45 in phase 3, and was the 66th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.

Read the detailed description

The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat anxiety in adults who have general anxiety disorder (GAD). This study looked at GAD relief in people who took vortioxetine.

The study enrolled 304 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 5 mg
  • Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 13 weeks. Participants made 7 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder
  • Mood Disorder
  • Affective Disorder
  • Anxiety Disorder
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a primary diagnosis of Generalized Anxiety Disorder according to the , 4th Edition, Text Revision (DSM-IV-TR®) criteria.
  • Has a Hamilton Anxiety Scale total score greater than or equal to 20 at Screening and Baseline.
  • Has a Hamilton Anxiety Scale score greater than or equal to 2 on both Item 1 (anxious mood) and Item 2 (tension) at Screening and Baseline.
  • Has a Montgomery-Åsberg Depression Rating Scale total score less than or equal to 16 at Screening and Baseline.

Exclusion criteria

Exclusion Criteria:

  • Has 1 or more of the following:

    • Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the (as assessed by the Mini International Neuropsychiatric Interview [MINI]).
    • Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR® and subject must have a negative urine drug screen prior to Baseline.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc.).
    • Any Axis II disorder that might compromise the study.
  • Is taking excluded medications.
  • Has a significant risk of suicide according to the investigator's opinion or has a score greater than or equal to 5 on Item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
  • Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a clinically significant unstable illness.
  • Has an , aspartate aminotransferase, or total level greater than 1.5 times the .
  • Has a serum creatinine of greater than 1.5 times the upper limit of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years.
  • Has thyroid stimulating hormone value outside the normal range at Screening and is deemed clinically significant by the investigator.
  • Has an abnormal .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
304 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

Interventions

  • Encapsulated vortioxetine immediate-release tablets

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8

    The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed by a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Week 8

  2. Clinical Global Impression Scale-Global Improvement at Week 8

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Week 8

  3. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Week 8

  4. Percentage of Responders in HAM-A Total Score at Week 8

    Response was defined as participants with a ≥50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Baseline and Week 8

  5. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Week 8

  6. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Week 8

  7. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1, 2, 4 and 6.

  8. Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed

    The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed by a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1 and 4

  9. Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1, 2, 4 and 6

  10. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means and P-values were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1, 2 and 4

  11. Percentage of Responders in HAM-A Total Score at Other Weeks Assessed

    Response was defined as participants with a ≥50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  12. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1, 2, 4 and 6

  13. Percentage of Participants in HAM-A Remission at Each Week Assessed

    Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Weeks 1, 2, 4, 6 and 8

  14. Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1, 2, 4, 6 and 8

  15. Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed

    The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 1, 4 and 8

  16. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2 and 4

  17. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  18. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  19. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  20. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  21. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  22. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  23. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

    Time frame: Baseline to Weeks 2, 4 and 8

  24. Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 33 investigative sites in the United States from 25 June 2008 to 06 March 2009.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 5 mg
Started152152
Treated151148
Completed114125
Not completed3827
Withdrew: Adverse event43
Withdrew: Lack of efficacy31
Withdrew: Noncompliance22
Withdrew: Protocol deviations34
Withdrew: Voluntary withdrawal97
Withdrew: Lost to follow-up168
Withdrew: Other12

Outcome measures

PrimaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8-13.16 ± 0.655-12.57 ± 0.646
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.518 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: 0.59 · 95% CI -1.20 to 2.38
SecondaryChange From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8

The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed by a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8-4.84 ± 0.392-5.06 ± 0.384
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.685 (Hierarchical testing stopped at the primary endpoint in the testing sequence, a nominal p-value is provided.) · Ls mean difference: -0.22 · 95% CI -1.29 to 0.85
SecondaryClinical Global Impression Scale-Global Improvement at Week 8

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Clinical Global Impression Scale-Global Improvement at Week 82.25 ± 0.1012.25 ± 0.099
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.984 (Statistical tests were 2-sided and results were presented with 95% confidence intervals with the estimated P-values at the 5% level of significance (ie, statistical significance if P\<0.05). No adjustments for multiplicity were made.) · Ls mean difference: 0.00 · 95% CI -0.27 to 0.28
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8-6.68 ± 0.618-6.35 ± 0.616
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.703 (Statistical tests were 2-sided and results were presented with 95% confidence intervals with the estimated P-values at the 5% level of significance (ie, statistical significance if P\<0.05). No adjustments for multiplicity were made.) · Ls mean difference: 0.33 · 95% CI -1.38 to 2.04
SecondaryPercentage of Responders in HAM-A Total Score at Week 8

Response was defined as participants with a ≥50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Week 8
percentage of participantsPlaceboVortioxetine 5 mg
Percentage of Responders in HAM-A Total Score at Week 850.053.1
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Regression, Logistic · p = 0.602 · Odds ratio (or): 1.131 · 95% CI 0.713 to 1.795Logistic regression with explanatory variables for treatment and Baseline HAM-A score.
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25-14.04 ± 1.104-14.05 ± 1.080
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.995 (Statistical tests were 2-sided and results were presented with 95% confidence intervals with the estimated P-values at the 5% level of significance (ie, statistical significance if P\<0.05). No adjustments for multiplicity were made.) · Ls mean difference: -0.01 · 95% CI -3.09 to 3.07
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8
scores on a scalePlaceboVortioxetine 5 mg
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 817.43 ± 2.13318.44 ± 2.091
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · Mixed model for repeated measurements · p = 0.731 (Statistical tests were 2-sided and results were presented with 95% confidence intervals with the estimated P-values at the 5% level of significance (ie, statistical significance if P\<0.05). No adjustments for multiplicity were made.) · Ls mean difference: 1.02 · 95% CI -4.79 to 6.83
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1, 2, 4 and 6.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=141, 144)-4.84 ± 0.415-4.59 ± 0.422
Week 2 (n=134, 142)-7.78 ± 0.542-8.22 ± 0.541
Week 4 (n=131, 135)-10.13 ± 0.590-9.82 ± 0.590
Week 6 (n=124, 129)-12.39 ± 0.632-11.61 ± 0.630
SecondaryChange From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed

The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed by a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=139, 142)-1.81 ± 0.269-2.07 ± 0.273
Week 4 (n=130, 135)-3.41 ± 0.328-3.72 ± 0.329
SecondaryClinical Global Impression Scale-Global Improvement at Other Weeks Assessed

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=141, 144)3.32 ± 0.0663.38 ± 0.066
Week 2 (n=134, 142)2.92 ± 0.0812.83 ± 0.081
Week 4 (n=131, 135)2.57 ± 0.0892.57 ± 0.089
Week 6 (n=124, 129)2.42 ± 0.0962.39 ± 0.095
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means and P-values were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1, 2 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=117, 116)-2.13 ± 0.484-2.46 ± 0.497
Week 2 (n=109, 114)-4.35 ± 0.566-4.02 ± 0.572
Week 4 (n=106, 108)-5.57 ± 0.587-5.38 ± 0.593
SecondaryPercentage of Responders in HAM-A Total Score at Other Weeks Assessed

Response was defined as participants with a ≥50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
percentage of participantsPlaceboVortioxetine 5 mg
Week 1 (n=141, 144)9.96.9
Week 2 (n=144, 145)22.924.1
Week 4 (n=144, 145)34.737.2
Week 6 (n=144, 145)47.245.5
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=71, 71)-5.39 ± 0.675-4.73 ± 0.648
Week 2 (n=70, 70)-8.37 ± 0.889-8.94 ± 0.873
Week 4 (n=67, 67)-10.90 ± 0.994-10.74 ± 0.980
Week 6 (n=63, 65)-13.60 ± 1.040-12.82 ± 1.021
SecondaryPercentage of Participants in HAM-A Remission at Each Week Assessed

Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Weeks 1, 2, 4, 6 and 8
Reported as:
Number · percentage of participants
Percentage of Participants in HAM-A Remission at Each Week Assessed
percentage of participantsPlaceboVortioxetine 5 mg
Week 1 (n-141, 144)2.10.7
Week 2 (n=144, 145)5.67.6
Week 4 (n=144, 145)15.312.4
Week 6 (n=144, 145)22.222.1
Week 8 (n=144, 145)22.225.5
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=141, 144)-0.37 ± 0.057-0.38 ± 0.058
Week 2 (n=134, 142)-0.75 ± 0.081-0.86 ± 0.081
Week 4 (n=131, 135)-1.15 ± 0.093-1.05 ± 0.092
Week 6 (n=124, 129)-1.45 ± 0.098-1.40 ± 0.097
Week 8 (n=113, 124)-1.72 ± 0.104-1.54 ± 0.102
SecondaryChange From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed

The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 1, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 1 (n=139, 142)-1.02 ± 0.226-1.09 ± 0.228
Week 4 (n=130, 135)-1.84 ± 0.273-2.28 ± 0.273
Week 8 (n=111, 124)-2.55 ± 0.316-2.62 ± 0.308
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2 and 4
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)11.96 ± 1.80314.06 ± 1.820
Week 4 (n=129, 134)17.12 ± 1.99316.22 ± 1.999
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)1.54 ± 1.3223.69 ± 1.336
Week 4 (n=129, 134)4.76 ± 1.4244.22 ± 1.432
Week 8 (n=113, 125)3.50 ± 1.6404.18 ± 1.609
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)5.03 ± 1.9014.90 ± 1.906
Week 4 (n=129, 134)8.65 ± 1.9665.19 ± 1.967
Week 8 (n=113, 125)10.02 ± 1.9987.74 ± 1.953
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)7.24 ± 1.7436.49 ± 1.755
Week 4 (n=129, 134)9.81 ± 1.7568.96 ± 1.761
Week 8 (n=113, 125)10.14 ± 1.9658.58 ± 1.915
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)2.79 ± 1.0953.61 ± 1.109
Week 4 (n=129, 134)4.85 ± 1.2041.76 ± 1.212
Week 8 (n=113, 125)6.14 ± 1.3913.90 ± 1.365
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)8.91 ± 1.52810.46 ± 1.555
Week 4 (n=129, 134)12.48 ± 1.65512.67 ± 1.671
Week 8 (n=113, 125)16.06 ± 1.82814.65 ± 1.805
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)14.54 ± 2.02813.25 ± 2.041
Week 4 (n=129, 134)16.00 ± 2.05515.00 ± 2.063
Week 8 (n=113, 125)21.64 ± 2.20219.01 ± 2.159
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a mixed model for repeated measurements (MMRM).

Time frame:
Baseline to Weeks 2, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed
scores on a scalePlaceboVortioxetine 5 mg
Week 2 (n=137, 143)10.32 ± 1.45511.72 ± 1.470
Week 4 (n=129, 134)12.58 ± 1.61015.12 ± 1.617
Week 8 (n=113, 125)17.95 ± 1.71616.91 ± 1.686
SecondaryHealth Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
participantsPlaceboVortioxetine 5 mg
Baseline: Any resource use3030
Baseline: Any hospitalization-related services10
Baseline: Hospitalization related to anxiety00
Baseline: Any sick leave810
Baseline: Sick leave related to anxiety74
Week 8: Any resource use2219
Week 8: Any hospitalization-related service01
Week 8: Hospitalization related to anxiety00
Week 8: Any sick leave46
Week 8: Sick leave related to anxiety21

Adverse events

Collected over Safety was assessed during the 8-week core treatment period and a 4-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/151 (2%)65/151 (43%)
Vortioxetine 5 mg—1/148 (0.7%)89/148 (60.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 5 mg
Abortion spontaneousPregnancy, puerperium and perinatal conditions2/1510/148
Therapeutic agent toxicityInjury, poisoning and procedural complications0/1511/148
Prostate infectionInfections and infestations1/1510/148
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboVortioxetine 5 mg
NauseaGastrointestinal disorders7/15137/148
HeadacheNervous system disorders13/15115/148
Dry mouthGastrointestinal disorders5/15112/148
DizzinessNervous system disorders5/15112/148
SomnolenceNervous system disorders3/1519/148
DiarrhoeaGastrointestinal disorders7/1518/148
NasopharyngitisInfections and infestations6/1518/148
InsomniaPsychiatric disorders6/1517/148
Blood pressure increasedInvestigations7/1511/148
Back painMusculoskeletal and connective tissue disorders1/1516/148

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 5 mgTotal
Mean41.4 ± 12.8141.0 ± 14.0541.2 ± 13.42
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 5 mgTotal
≤55 years128129257
>55 years242347
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 5 mgTotal
Female97103200
Male5549104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 5 mgTotal
Caucasian (White, including Hispanic)131123254
Black172441
Asian235
American Indian or Alaska Native022
Native Hawaiian/ Other Pacific Islander202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 5 mgTotal
Hispanic/Latino242650
Non-Hispanic/Non-Latino128126254
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 5 mgTotal
United States152152304
Weight
Weight(kg)PlaceboVortioxetine 5 mgTotal
Mean83.68 ± 20.91680.10 ± 20.29681.89 ± 20.652
Height
Height(cm)PlaceboVortioxetine 5 mgTotal
Mean167.73 ± 8.765167.72 ± 9.158167.73 ± 8.949

8 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • Anaheim, California, United States
  • Arcadia, California, United States
  • Irvine, California, United States
  • National City, California, United States
  • Sherman Oaks, California, United States
  • Upland, California, United States
  • Washington, District of Columbia, United States
  • Bradenton, Florida, United States
  • Coral Gables, Florida, United States
  • North Miami, Florida, United States
  • St Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Oak Brook, Illinois, United States
  • Park Ridge, Illinois, United States
  • Lafayette, Indiana, United States
  • Wichita, Kansas, United States
  • Baltimore, Maryland, United States
  • Fall River, Massachusetts, United States
  • Worcester, Massachusetts, United States
  • Flowood, Mississippi, United States
  • Bronx, New York, United States
  • Brooklyn, New York, United States
  • New York, New York, United States
  • Morganton, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Portland, Oregon, United States
  • Lincoln, Rhode Island, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • San Antonio, Texas, United States
  • Charleston, West Virginia, United States
09

References and documents

Publications

  • Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66. doi: 10.1016/j.euroneuro.2012.07.011. Epub 2012 Aug 15. PubMed 22901736 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jan 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2008
First posted
Aug 13, 2008
Start
Jun 2008
Primary completionActual
Jan 2009
CompletionActual
Mar 2009
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00734071
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 13, 2008
Start date
Jun 2008
Primary completion
Jan 2009
Completion
Mar 2009
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion